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Summary Enterobacter amnigenus and Leclercia adecarboxylata are Gram-negative aerobic
bacilli of the family Enterobacteriaceae that have been isolated from water and, rarely, from
various clinical specimens. Absidia is a filamentous fungus of the class Zygomycetes that is
ubiquitous in nature and can cause infection, primarily in immunocompromised hosts. Here, we
describe an infection of the left lower limb caused by E. amnigenus and L. adecarboxylata with
subsequent isolation of Absidia spp. in a patient with multiple traumatic injuries after a major
motor vehicle accident. The severity of the clinical picture made amputation necessary, despite
aggressive anti-infective therapy with both antibacterial and antifungal agents. Prompt diagnosis
and management are mandatory in order to minimize morbidity and even mortality, and reduce
the social and economic cost.
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Enterobacter amnigenus and Leclercia adecarboxylata are
motile, Gram-negative aerobic bacilli (GNAB) of the family
Enterobacteriaceae. They are ubiquitous in nature and
have been isolated from water and soil and also from various
clinical specimens, including blood, feces, sputum and
wounds.1,2 E. amnigenus has been grown in samples
from a few patients with sepsis3 and other infections.4 L.
adecarboxylata has been found to cause infection both in
immunocompromised hosts (bacteremia) and in otherwisePublished by Elsevier Ltd. All rights reserved.
Figure 1 Stump of the left lower limb at the time of the second
amputation surgery. The presence of grayish plaques with necro-
tic edges in two distinct areas (delimited by the black line)
suggested Absidia etiology, thereafter confirmed by direct
microscopy.
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infections of the lower limbs).5 Both these GNAB are sus-
ceptible to all the antimicrobial agents that are generally
active against Enterobacteriaceae (most beta-lactams,
aminoglycosides, fluoroquinolones, antifolates, chloram-
phenicol, nitrofurantoin), except for fosfomycin.6,7
Absidia species — like other species of the order Mucorales
(i.e. Mucor and Rhizopus) — are filamentous fungi of the class
Zygomycetes that are ubiquitous in nature, and have been
isolated from humid soil, plant debris and air.8 Absidia spp.
are common laboratory contaminants and only Absidia cor-
ymbifera is considered pathogenic for humans. A. corymbi-
fera, for which reclassification as Mycocladus corymbifer has
been recently proposed,9 very rarely causes infection in the
immunocompetent host, whereas its growth in culture from
clinical samples of immunosuppressed and diabetic subjects
should be regarded as potentially significant.10 Traditionally,
amphotericin B has been the only effective antifungal drug
against Zygomycetes, which are resistant to flucytosine,
caspofungin, fluconazole and voriconazole;11 however, the
new triazole agent posaconazole has a good activity.12
Here, we describe a mixed infection of the left lower
limb caused by E. amnigenus and L. adecarboxylata with
subsequent isolation of Absidia spp. in a patient with severe
polytrauma.
Case report
A 37-year-old Caucasian male — body weight approximately
65 kg — was admitted to our Emergency Department (ED)
after a major motor vehicle accident. He had the following
multiple injuries: Gustillo—Anderson type II open fracture
of the left distal femur; type IIIB open fracture of the left
distal tibia with bone loss; and mangled left foot with multi-
ple fractures and extensive soft-tissue involvement. The
patient was rescued on the road, so no farm contamination
was expected. In the ED, he was treated with irrigation and
de´bridement (I&D). In an attempt to save the left lower limb,
open reduction and internal fixation (ORIF) of the foot and
distal tibia fractures was performed, together with external
fixation of the femur.
Intravenous empiric antibiotic therapy was promptly
initiated according to hospital protocol: teicoplanin 400 mg/
day (after a loading dose of 800 mg), tobramicin 300 mg/day
and metronidazole 500 mg four times per day. Tetanus
prophylaxis was not supplied as the patient had received a
booster dose one year before.
Angiography and a microsurgical referral were obtained;
it was decided to wait for necrosis delimitation and a course
of hyperbaric oxygen therapy was initiated.
After 14 days, the clinical situation showed no possibility
of limb salvage and a below-knee amputation was performed.
Multiple surgical samples of the wound (swabs, de´brided
tissue) were collected for microbiological cultures, which
grew two enterobacterial strains after isolation on Columbia
blood agar plates incubated at 37 8C for 48 hours. Their
identification as E. amnigenus and L. adecarboxylata was
performed by standard techniques, that is, biochemical
identification and susceptibility testing using a commercial
automated system (Vitek 2, bioMe´rieux, France). Therefore,
targeted antibiotic therapy with intravenous piperacillin/tazobactam 4.5 g three times per day was undertaken in
place of the previous treatment.
After seven days, a second surgery, involving I&D plus re-
amputation on a more proximal level (but always below
knee), was needed to control a recalcitrant infection of
the stump; grayish plaques with necrotic edges had appeared
and rapidly increased in size (Figure 1). This type of skin
lesion is suggestive of Absidia infection.10 New intra-opera-
tive samples of the wound were collected. The culture, after
inoculation onto Sabouraud dextrose agar, grew a fungus that
was consistent with Absidia spp. on the basis of both colony
morphology (woolly grayish surface) and microscopic fea-
tures (large non-septate filamentous hyphae, branched spor-
angiophores with flask-shaped apophysis just below the
columella).10
Antifungal therapy with liposomal amphotericin B 3 mg/kg
(200 mg) per day was prescribed at that time and conti-
nued for 15 days. Thereafter, final ORIF of the distal femur
was performed and control of stump infection was finally
achieved.
Eighteen months after the final surgery, no signs of infec-
tion were present at both stump and femur level.
Discussion
In the medical literature, there are scant citations on human
infections associated with particular Enterobacteriaceae and
filamentous fungi. E. amnigenus, previously called Entero-
bacter H3, was reported to have caused sepsis only in two
patients, after blood transfusion3 and heart transplanta-
tion.13 Other site infections (cholecystitis, cystitis, lympha-
denitis, osteomyelitis) have also been reported to be caused
by this microorganism.4 During the past decade, L. adecar-
boxylata has most often been isolated from clinical speci-
mens as part of mixed flora in trauma- or diabetes-associated
wound infections of the lower limbs5,14 and in immunosup-
pressed patients with sepsis and abdominal infections.5,15 It
is possible that the development of commercially available
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accurate methods (DNA—DNA hybridization, specific bacter-
iophage) has contributed to the increasingly frequent iden-
tification of L. adecarboxylata after isolation from clinical
specimens, as L. adecarboxylata can be easily confused with
Escherichia coli in the standard laboratory.
Infections with Absidia spp. usually occur in immunocom-
promised hosts, such as patients with acute leukemia. They
manifest with respiratory, gastrointestinal, cerebral or sinu-
sal symptoms, and are often fatal, even if aggressive anti-
fungal treatment is used.16 Moreover, skin and soft-tissue
infections have been described in HIV-infected subjects17 and
in burn patients, where their occurrence is facilitated by
moist and humid conditions, as in the case of occlusive
bandages.18
We described a mixed infection of the left lower limb
caused by E. amnigenus and L. adecarboxylata with subse-
quent isolation of Absidia spp. in a patient with severe
traumatic injuries. We cannot exclude that the filamentous
fungus was present before the first surgical procedure, as
infections with Absidia spp. can be caused even by traumatic
implantation through skin—ground contact in previously
healthy subjects. Such cases can be fatal19 or require aggres-
sive surgical treatment (drainage, de´bridement, resection),
including amputation, despite appropriate antifungal ther-
apy with amphotericin B or posaconazole.20,21 This empha-
sizes the need for early diagnosis and, subsequently,
prolonged treatment in order to obtain a successful out-
come.22 Otherwise, it is also possible that our patient’s
Absidia strain was transmitted nosocomially during surgery
or hospital stay, as previously described in kidney, liver and
bone marrow transplantation subjects.23—25 Our patient had
no pre-existing evidence of immune suppression, but acute
post-traumatic shock could lead to a low-to-moderate
depression of immune function, which, in turn, favors the
appearance of a severe Absidia infection of the lower limb.
Moreover, a typical risk factor for mycetic and mold contam-
ination, that is, a recently prescribed broad-spectrum anti-
biotic therapy, must be considered for our patient.
As far as the susceptibility patterns of our enterobacterial
isolates are concerned, E. amnigenuswas fully susceptible to
aminoglycosides, aztreonam, carbapenems, third- and forth-
generation cephalosporins, cotrimoxazole, fluoroquinolones
and ureidopenicillins, and resistant to aminopenicillins and
first-generation cephalosporins (cefazolin) only, as has some-
times been reported.6 On the other hand, L. adecarboxylata
was fully susceptible to all tested antimicrobial agents (beta-
lactams including aminopenicillins and first-generation
cephalosporins, aminoglycosides, fluoroquinolones, cotri-
moxazole), which are generally effective against E. coli as
well.7 Despite the use of antibiotics that were active in vitro
against both Enterobacteriaceae (first tobramycin, then
piperacillin/tazobactam) and although therapy with full-
dose liposomal amphotericin B was started when the coex-
istence of Absidia emerged, the severe clinical picture con-
tinued and it was not possible to rescue the limb from
amputation.
This case report on severe post-traumatic infection of a
lower limb emphasizes the importance of both prompt wound
de´bridement and systemic antibacterial therapy. Addition-
ally, fundamental microbiological work-up for bacterial and/
or fungal identification and consequent targeted antimicro-bial therapy are essential in order to minimize morbidity and
even mortality, and reduce the need for major surgical
procedures.
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